Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01151748

Enrollment

Registered

2010-06-28

Start date

2010-09-30

Completion date

2012-03-31

Last updated

2012-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Cancer, Retinoblastoma

Brief summary

Phase II study of selective intra-arterial infusion of chemotherapy for intraocular retinoblastoma

Interventions

PROCEDUREIntra-arterial infusion of chemotherapy

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

No minimum to 18 Years

Healthy volunteers

Inclusion criteria

1. Patients diagnosed with advanced intraocular retinoblastoma (International Retinoblastoma Classification group D or E\*). 2. Patients with tumor recurrence or vitreous seeding following completion of systemic chemotherapy or previous radiation therapy.

Exclusion criteria

1. Congenital brain anomaly identified on MRI. 2. History of systemic coagulopathy. 3. Evidence of extra ocular retinoblastoma on clinical examination or neuroimaging.

Design outcomes

Primary

Measure	Time frame
Response: Globe salvage rate (Eyes saved/Eyes treated). This will be determined by clinical ocular examination.	Follow-up will be performed for one year from treatment date.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026